HMO degradation by Bifidobacterium indirectly supports other beneficial bacteria such as Lactobacillus species through cross-feeding mechanisms, amplifying the positive impact on overall microbiome composition. Fermentation of HMOs produces beneficial short-chain fatty acids, most notably acetate, propionate, and butyrate, which promote intestinal barrier integrity, limit inflammation, serve as energy substrates for intestinal epithelial cells, and modulate immune responses 1,2.
Clinical intervention trials have demonstrated that adding HMOs to infant formula brings the gut microbiota of formula-fed infants closer to that of breastfed infants 3.
Beyond microbiome support, HMOs can enhance intestinal barrier function through multiple mechanisms, including promoting intestinal maturation, reducing intestinal permeability, and supporting the mucus layer 4,2. Preclinical studies demonstrate that HMOs positively influence gut maturation and reduce permeability by modulating glycocalyx components, inducing mucin expression, and suppressing pro-inflammatory cytokines 5.